Abstract

Recent research has demonstrated that small heat shock protein (sHsp) phosphorylation plays a variety of roles in neural cells. While the phosphorylation of serine 16 (Ser16) is blocked, Hsp20 no longer has neuroprotective effects. To further investigate the mechanism underlying this process, oxygen-glucose deprivation and reperfusion (OGD/R) was used with human SH-SY5Y cells and mouse N2a neuroblastoma cells. When SH-SY5Y and N2a cells were transfected with pEGFP-Hsp20(WT), pEGFP-Hsp20(S16A), and pEGFP-Hsp20(S16D) plasmids, the Golgi apparatus (GA) became more swollen and scattered, and many small fragments formed in the MOCK and S16A groups after OGD/R (P < 0.05). Meanwhile, the endoplasmic reticulum (ER) network was reduced, and the lamellar structure increased. However, these changes were not as obvious in the WT and S16D groups. Additionally, after OGD/R, Golgi Stress related protein contents were increased in the WT and S16D groups compared with the MOCK and S16A groups (P < 0.05). However, ER Stress related protein contents were decreased in the WT and S16D groups compared with the MOCK and S16A groups (P < 0.05). Our study demonstrates that Hsp20 phosphorylation on Ser16 protects against not only OGD/R-induced GA fragmentation in SH-SY5Y cells and N2a cells via Golgi stress but also OGD/R-induced ER structural changes in SH-SY5Y cells via ER stress. These findings suggest that Hsp20 is a potential drug target for ischemia stroke treatment.

Highlights

  • Ischemic stroke is the most common type of stroke

  • Phosphorylation of Hsp20Ser16 exerts protective effect reperfusion for 6, 12, 24 or 36 hours following OGD, the apoptosis rate of SH-SY5Y cells was increased to 6.88%, 13.35%, 18.71% and 20.65%

  • After reperfusion for 24 or 36 hours, the apoptosis rates of SH-SY5Y cells were decreased in the WT and S16D groups compared with the MOCK groups (P < 0.05)

Read more

Summary

Introduction

Ischemic stroke is the most common type of stroke. Recent studies have shown that in China, the mortality rate of ischemic stroke patients is approximately 3.3–5.2% during the first month after disease onset and is 11.4–15.4% during the first year after disease onset. Treatment, rehabilitation and prevention of ischemic stroke should be emphasized [1]. The ultra-early use of recombinant tissue plasminogen activator for intravenous thrombolysis is the most effective drug treatment to improve the outcome of acute ischemic stroke.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call